JOP20190080A1 - مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها - Google Patents
مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتهاInfo
- Publication number
- JOP20190080A1 JOP20190080A1 JOP/2019/0080A JOP20190080A JOP20190080A1 JO P20190080 A1 JOP20190080 A1 JO P20190080A1 JO P20190080 A JOP20190080 A JO P20190080A JO P20190080 A1 JOP20190080 A1 JO P20190080A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- pyrazol
- pyrimidin
- substituted
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
يتعلق الاختراع الحالي بـمركبات 6-(1H-pyrazol-1-yl)pyrimidin-4-amine مستبدلة من الصيغة العامة (I) كما وصف وعرف هنا، وطرق لتحضير المركبات المذكورة، ومركبات وسيطة مفيدة لتحضير المركبات المذكورة، وتركيبات صيدلية وتوليفات تشمل المركبات المذكورة، واستخدام المركبات المذكورة لتصنيع تركيبات صيدلية للمعالجة أو الوقاية من أمراض، تحديدا للمعالجة و/أو الوقاية من أمراض قلبية عائية وكلوية، كعامل منفرد أو في توليفة مع مكونات فعالة أخرى.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16193953 | 2016-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190080A1 true JOP20190080A1 (ar) | 2019-04-11 |
Family
ID=57136772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0080A JOP20190080A1 (ar) | 2016-10-14 | 2017-06-16 | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
Country Status (28)
Country | Link |
---|---|
US (2) | US11208400B2 (ar) |
EP (1) | EP3526212B1 (ar) |
JP (1) | JP2019532961A (ar) |
KR (1) | KR20190065402A (ar) |
CN (1) | CN110191884A (ar) |
AR (1) | AR109947A1 (ar) |
AU (1) | AU2017341324A1 (ar) |
BR (1) | BR112019007496A2 (ar) |
CA (1) | CA3040166A1 (ar) |
CL (1) | CL2019001004A1 (ar) |
CO (1) | CO2019003761A2 (ar) |
CR (1) | CR20190192A (ar) |
CU (1) | CU24518B1 (ar) |
DO (1) | DOP2019000099A (ar) |
EA (1) | EA201990947A1 (ar) |
EC (1) | ECSP19026563A (ar) |
GE (1) | GEP20217269B (ar) |
IL (1) | IL265923A (ar) |
JO (1) | JOP20190080A1 (ar) |
MA (1) | MA46514A (ar) |
MX (1) | MX2019004347A (ar) |
PE (1) | PE20191549A1 (ar) |
PH (1) | PH12019500808A1 (ar) |
SG (1) | SG11201903305XA (ar) |
TN (1) | TN2019000114A1 (ar) |
TW (1) | TW201825477A (ar) |
UY (1) | UY37444A (ar) |
WO (1) | WO2018069222A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110734428A (zh) * | 2019-10-24 | 2020-01-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
CN115403524A (zh) * | 2021-05-26 | 2022-11-29 | 浙江省化工研究院有限公司 | 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法 |
WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
EP1175425A2 (en) | 1999-01-21 | 2002-01-30 | The Board Of Regents, The University Of Texas System | Inhibitors of intestinal apical membrane na/phosphate co-transportation |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
EP2146967A2 (en) * | 2007-04-16 | 2010-01-27 | Serenex, Inc. | Tetrahydroindole and tetrahydroindazole derivatives |
JP2008296610A (ja) | 2007-05-29 | 2008-12-11 | Toyota Motor Corp | 車両用動力伝達装置の制御装置 |
RU2010148531A (ru) * | 2008-04-29 | 2012-06-10 | Новартис АГ (CH) | Способы мониторинга модуляции киназной активности рецептора фактора роста фибробластов и применения указанных способов |
US8541424B2 (en) | 2008-12-23 | 2013-09-24 | Abbott Laboratories | Anti-viral compounds |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
AU2011219746B2 (en) | 2010-02-27 | 2015-04-23 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
MX2012015252A (es) * | 2010-06-30 | 2013-05-30 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc. |
WO2012006474A2 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590656B1 (en) | 2010-07-07 | 2017-11-15 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590655B1 (en) | 2010-07-07 | 2015-06-24 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2012006477A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2591354B1 (en) * | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
BR112013000596A2 (pt) | 2010-07-09 | 2019-09-24 | Bayer Intelectual Property Gmbh | piridinas e tiazinas fusionadas e seus usos. |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
MX342521B (es) | 2011-10-27 | 2016-10-03 | Astellas Pharma Inc | Derivado de n-tienilbenzamida sustituido con aminoalquilo. |
WO2013082756A1 (en) | 2011-12-06 | 2013-06-13 | Leo Pharma A/S | Phosphate transport inhibitors ii |
US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
TWI582083B (zh) * | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
HUE040696T2 (hu) | 2014-11-03 | 2019-03-28 | Bayer Pharma AG | Hidroxialkil-szubsztituált feniltriazol-származékok és alkalmazásuk |
CN105631664A (zh) | 2014-11-26 | 2016-06-01 | 华为终端(东莞)有限公司 | 一种非接触支付方法、装置及*** |
US10266517B2 (en) * | 2014-12-23 | 2019-04-23 | Dana-Farber Cancer Institute, Inc. | Pyrimidines as EGFR inhibitors and methods of treating disorders |
JP7068288B2 (ja) | 2016-10-14 | 2022-05-16 | ノバルティス アーゲー | 4-(2-((1r,2r)-2-ヒドロキシシクロヘキシルアミノ)ベンゾチアゾール-6-イルオキシ)-n-メチルピコリンアミドの結晶形 |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
CN110325182B (zh) | 2016-10-14 | 2023-05-23 | 蒙得维的亚巴斯德研究所 | 使用多能抗炎和代谢调节剂治疗炎症相关病症的方法 |
-
2017
- 2017-06-16 JO JOP/2019/0080A patent/JOP20190080A1/ar unknown
- 2017-10-09 KR KR1020197013647A patent/KR20190065402A/ko not_active Application Discontinuation
- 2017-10-09 CA CA3040166A patent/CA3040166A1/en active Pending
- 2017-10-09 MX MX2019004347A patent/MX2019004347A/es unknown
- 2017-10-09 PE PE2019000822A patent/PE20191549A1/es unknown
- 2017-10-09 GE GEAP201715076A patent/GEP20217269B/en unknown
- 2017-10-09 SG SG11201903305XA patent/SG11201903305XA/en unknown
- 2017-10-09 WO PCT/EP2017/075630 patent/WO2018069222A1/en unknown
- 2017-10-09 BR BR112019007496A patent/BR112019007496A2/pt not_active Application Discontinuation
- 2017-10-09 EA EA201990947A patent/EA201990947A1/ru unknown
- 2017-10-09 JP JP2019519748A patent/JP2019532961A/ja active Pending
- 2017-10-09 CU CU2019000035A patent/CU24518B1/es unknown
- 2017-10-09 TN TNP/2019/000114A patent/TN2019000114A1/en unknown
- 2017-10-09 CR CR20190192A patent/CR20190192A/es unknown
- 2017-10-09 MA MA046514A patent/MA46514A/fr unknown
- 2017-10-09 EP EP17780751.8A patent/EP3526212B1/en active Active
- 2017-10-09 AU AU2017341324A patent/AU2017341324A1/en not_active Abandoned
- 2017-10-09 US US16/341,410 patent/US11208400B2/en active Active
- 2017-10-09 CN CN201780074126.5A patent/CN110191884A/zh active Pending
- 2017-10-12 TW TW106134859A patent/TW201825477A/zh unknown
- 2017-10-13 AR ARP170102862A patent/AR109947A1/es unknown
- 2017-10-13 UY UY0001037444A patent/UY37444A/es not_active Application Discontinuation
-
2019
- 2019-04-08 IL IL265923A patent/IL265923A/en unknown
- 2019-04-12 EC ECSENADI201926563A patent/ECSP19026563A/es unknown
- 2019-04-12 CO CONC2019/0003761A patent/CO2019003761A2/es unknown
- 2019-04-12 CL CL2019001004A patent/CL2019001004A1/es unknown
- 2019-04-12 DO DO2019000099A patent/DOP2019000099A/es unknown
- 2019-04-12 PH PH12019500808A patent/PH12019500808A1/en unknown
-
2021
- 2021-11-04 US US17/519,329 patent/US20230065629A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20230065629A1 (en) | 2023-03-02 |
JP2019532961A (ja) | 2019-11-14 |
WO2018069222A1 (en) | 2018-04-19 |
CN110191884A (zh) | 2019-08-30 |
BR112019007496A2 (pt) | 2019-09-10 |
CU24518B1 (es) | 2021-06-08 |
TN2019000114A1 (en) | 2020-10-05 |
GEP20217269B (en) | 2021-06-25 |
CR20190192A (es) | 2019-09-02 |
CO2019003761A2 (es) | 2019-04-30 |
IL265923A (en) | 2019-06-30 |
PH12019500808A1 (en) | 2020-01-20 |
SG11201903305XA (en) | 2019-05-30 |
US11208400B2 (en) | 2021-12-28 |
AU2017341324A1 (en) | 2019-05-02 |
MX2019004347A (es) | 2019-07-01 |
PE20191549A1 (es) | 2019-10-24 |
CU20190035A7 (es) | 2019-11-04 |
US20200055842A1 (en) | 2020-02-20 |
DOP2019000099A (es) | 2019-07-15 |
ECSP19026563A (es) | 2019-04-30 |
KR20190065402A (ko) | 2019-06-11 |
EA201990947A1 (ru) | 2019-08-30 |
EP3526212B1 (en) | 2021-12-22 |
AR109947A1 (es) | 2019-02-06 |
UY37444A (es) | 2018-05-31 |
CL2019001004A1 (es) | 2019-08-30 |
CA3040166A1 (en) | 2018-04-19 |
TW201825477A (zh) | 2018-07-16 |
EP3526212A1 (en) | 2019-08-21 |
MA46514A (fr) | 2019-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
MX2020001403A (es) | Nuevos derivados de quinolina. | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
PH12019502851A1 (en) | New azaquinoline derivatives | |
PH12016501807A1 (en) | Novel compounds | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
PH12017501133A1 (en) | Pyrazolopyridinamines | |
PH12020500134A1 (en) | Dihydrooxadiazinones | |
PH12016500054A1 (en) | Substituted pyrazolo-pyridinamines | |
SA518400501B1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) | |
WO2015150449A3 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 | |
PH12019500808A1 (en) | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
MA39762A (fr) | Nouveaux composés | |
TN2014000091A1 (en) | Amino-substituted imidazopyridazines |